Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21502923rdf:typepubmed:Citationlld:pubmed
pubmed-article:21502923lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:21502923lifeskim:mentionsumls-concept:C0015177lld:lifeskim
pubmed-article:21502923lifeskim:mentionsumls-concept:C0982327lld:lifeskim
pubmed-article:21502923lifeskim:mentionsumls-concept:C0021747lld:lifeskim
pubmed-article:21502923lifeskim:mentionsumls-concept:C0035525lld:lifeskim
pubmed-article:21502923lifeskim:mentionsumls-concept:C0524910lld:lifeskim
pubmed-article:21502923lifeskim:mentionsumls-concept:C0036043lld:lifeskim
pubmed-article:21502923lifeskim:mentionsumls-concept:C0162643lld:lifeskim
pubmed-article:21502923lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:21502923lifeskim:mentionsumls-concept:C0205099lld:lifeskim
pubmed-article:21502923pubmed:issue5lld:pubmed
pubmed-article:21502923pubmed:dateCreated2011-4-19lld:pubmed
pubmed-article:21502923pubmed:abstractTextTo assess the safety and efficacy of 48 weeks of re-treatment with peginterferon ?-2a (40 kD) plus ribavirin in previously treated hepatitis C virus (HCV) genotype 1 patients.lld:pubmed
pubmed-article:21502923pubmed:languageenglld:pubmed
pubmed-article:21502923pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21502923pubmed:citationSubsetIMlld:pubmed
pubmed-article:21502923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21502923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21502923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21502923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21502923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21502923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21502923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21502923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21502923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21502923pubmed:statusMEDLINElld:pubmed
pubmed-article:21502923pubmed:monthMaylld:pubmed
pubmed-article:21502923pubmed:issn1473-5687lld:pubmed
pubmed-article:21502923pubmed:authorpubmed-author:UrbanekPetrPlld:pubmed
pubmed-article:21502923pubmed:authorpubmed-author:TietzAndreasAlld:pubmed
pubmed-article:21502923pubmed:authorpubmed-author:HusaPetrPlld:pubmed
pubmed-article:21502923pubmed:authorpubmed-author:MessingerDiet...lld:pubmed
pubmed-article:21502923pubmed:authorpubmed-author:OltmanMarianMlld:pubmed
pubmed-article:21502923pubmed:authorpubmed-author:IvanovskiLjub...lld:pubmed
pubmed-article:21502923pubmed:authorpubmed-author:RehákVratisla...lld:pubmed
pubmed-article:21502923pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21502923pubmed:volume23lld:pubmed
pubmed-article:21502923pubmed:ownerNLMlld:pubmed
pubmed-article:21502923pubmed:authorsCompleteYlld:pubmed
pubmed-article:21502923pubmed:pagination375-81lld:pubmed
pubmed-article:21502923pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:21502923pubmed:meshHeadingpubmed-meshheading:21502923...lld:pubmed
pubmed-article:21502923pubmed:meshHeadingpubmed-meshheading:21502923...lld:pubmed
pubmed-article:21502923pubmed:meshHeadingpubmed-meshheading:21502923...lld:pubmed
pubmed-article:21502923pubmed:meshHeadingpubmed-meshheading:21502923...lld:pubmed
pubmed-article:21502923pubmed:meshHeadingpubmed-meshheading:21502923...lld:pubmed
pubmed-article:21502923pubmed:meshHeadingpubmed-meshheading:21502923...lld:pubmed
pubmed-article:21502923pubmed:meshHeadingpubmed-meshheading:21502923...lld:pubmed
pubmed-article:21502923pubmed:meshHeadingpubmed-meshheading:21502923...lld:pubmed
pubmed-article:21502923pubmed:meshHeadingpubmed-meshheading:21502923...lld:pubmed
pubmed-article:21502923pubmed:meshHeadingpubmed-meshheading:21502923...lld:pubmed
pubmed-article:21502923pubmed:meshHeadingpubmed-meshheading:21502923...lld:pubmed
pubmed-article:21502923pubmed:meshHeadingpubmed-meshheading:21502923...lld:pubmed
pubmed-article:21502923pubmed:meshHeadingpubmed-meshheading:21502923...lld:pubmed
pubmed-article:21502923pubmed:meshHeadingpubmed-meshheading:21502923...lld:pubmed
pubmed-article:21502923pubmed:meshHeadingpubmed-meshheading:21502923...lld:pubmed
pubmed-article:21502923pubmed:meshHeadingpubmed-meshheading:21502923...lld:pubmed
pubmed-article:21502923pubmed:meshHeadingpubmed-meshheading:21502923...lld:pubmed
pubmed-article:21502923pubmed:meshHeadingpubmed-meshheading:21502923...lld:pubmed
pubmed-article:21502923pubmed:year2011lld:pubmed
pubmed-article:21502923pubmed:articleTitleEfficacy and safety of peginterferon ?-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe.lld:pubmed
pubmed-article:21502923pubmed:affiliationDepartment of Infectious Diseases, Faculty Hospital and Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic. phusa@fnbrno.czlld:pubmed
pubmed-article:21502923pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21502923pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:21502923pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:21502923pubmed:publicationTypeMulticenter Studylld:pubmed